GENinCode, the genetic testing company focused on cardiovascular disease, has been trying to convert growing clinical interest into sustained Revenue growth. Its annual results for the year ended 31 December 2025, reported in June 2026, showed higher sales and better margins but a wider loss, and the shares fell about 18% to 0.94p on the day of publication as investors reacted to a flat start to 2026.
What the company does
GENinCode develops polygenic and genetic risk assessment tests. Its main products are LIPID inCode, used to diagnose familial hypercholesterolaemia and other lipid disorders, and CARDIO inCode, which provides a polygenic risk score for coronary artery disease. The company also offers ROCA, a risk algorithm used to help assess ovarian cancer risk. It operates in the UK, Europe and the United States.
Latest developments
In the results statement, GENinCode said more than 70 US institutions and clinics had been onboarded, up from more than 45 at the end of 2025. It highlighted a decision by the American College of Cardiology and American Heart Association to include coronary artery disease polygenic risk scores as a risk-enhancing Factor in their guidance, which the company sees as supportive for CARDIO inCode.
The company also reported a Partnership with Thermo Fisher to sell CARDIO inCode in the US and in Europe, the Middle East and Africa, with pricing and distribution terms still under discussion at the time. In the UK, around 2,800 familial hypercholesterolaemia tests had been carried out in the North East and North Cumbria over 24 months, identifying more than 500 positive patients, and ROCA secured its first NHS commercial contract with University College London Hospitals.
GENinCode had said it expected to make a De Novo submission to the US Food and Drug Administration in the third quarter of 2026, with approval targeted by the end of the year. The latest search did not find confirmation of the submission's status.
Financial and Dividend picture
For 2025, revenue rose 14% to £3.1 million from £2.7 million, driven by growth in the US and Europe. Gross Profit increased to £1.8 million and the gross Margin improved to 59% from 53%. However, the adjusted EBITDA loss widened to £4.9 million from £4.4 million, and the loss for the year rose to £5.7 million from £4.4 million.
Cash at the year end was £0.8 million, but the company raised £4.7 million after the period end, with shareholders approving the issue at a general meeting in February 2026. Trading from January to April 2026 was broadly flat year on year, as lower NHS and Catalonia pilot revenue offset growth elsewhere. For 2026 as a whole, management expected revenue growth, improved margins and lower EBITDA losses. No dividend is paid.
Sector and index context
GENinCode is one of the smaller diagnostics companies in the FTSE AIM All Share Index. Polygenic risk scoring is a developing field, and wider adoption depends on clinical guidelines, regulatory approvals and reimbursement by health systems and insurers.
Key risks
The company is loss-making with a limited cash buffer, so further fundraising may be needed. Regulatory timelines in the US could slip, and commercial terms with Thermo Fisher had not been finalised. Revenue from public health pilots can be uneven.
What to watch next
The key milestone is progress on the FDA De Novo application. Investors will also look for confirmation of the Thermo Fisher commercial terms and evidence of revenue growth in the second half of 2026.






Please wait processing your request...